Abstract
THE massive health problem associated with cigarette smoking is exacerbated by the addictive properties of tobacco smoke and the limited success of current approaches to cessation of smoking1. Yet little is known about the neuropharmacological actions of cigarette smoke that contribute to smoking behaviour, or why smoking is so prevalent in psychiatric disorders2 and is associated with a decreased risk of Parkinson's disease3. Here we report that brains of living smokers show a 40% decrease in the level of monoamine oxidase B (MAO B; EC 1.4.3.4) relative to non-smokers or former smokers. MAO B is involved in the breakdown of dopamine, a neurotransmitter implicated in reinforcing and motivating behaviours as well as movement. MAO B inhibition is therefore associated with enhanced activity of dopamine4, as well as with decreased production of hydrogen peroxide, a source of reactive oxygen species5. We propose that reduction of MAO B activity may synergize with nicotine to produce the diverse behavioural and epidemiological effects of smoking.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Henningfield, J. E., Schuh, L. M. & Jarvik, M. E. in Psychopharmacology, the Fourth Generation of Progress (eds Bloom, F. W. & Kupfer, D. J.) Ch. 147, 1715–1729 (Raven, New York 1995).
Hughes, J. R., Hatsukama, D. K., Mitchell, J. E. & Dahlgren, L. A. Am. J. Psychiatry 143, 993–997 (1986).
Morens, D. M., Grandinetti, A., Reed, D., White, L. R. & Ross, G. W. Neurology 45, 1041–1051 (1995).
Berry, M. D., Juorio, A. V. & Paterson, I. A. Prog. Neurobiol. 42, 375–391 (1994).
Reiter, R. J. FASEB J. 9, 526–533 (1995).
Fowler, J. S. et al. J. Neurochem. 51, 1524–1534 (1988).
Fowler, J. S. et al. J. nucl. Med. 36, 1255–1262 (1995).
Patlak, C. S., Blasberg, R. G. & Fenstermacher, J. D. J. cereb. Blood Flow Metab. 3, 1–7 (1983).
Yamashita, K., Kobayashi, S., Yamaguchi, S., Kitani, M. & Tsunematsu, T. Gerontology 34, 199–204 (1988).
Wang, G.-J., Volkow, N. D., Wolf, A. P., Brodie, J. D. & Hitzemann, R. J. J. nucl. Med. 35, 1457–1466 (1994).
Stapleton, J. M. et al. National Institute on Drug Abuse Res Monogr. Ser. Vol. 132, 106 (Department of Health and Human Services, Washington DC, 1993).
Riederer, P. & Youdim, M. B. H. J. Neurochem. 46, 1359–1365 (1986).
Oreland., L., Fowler, C. J. & Schalling, D. Life Sci. 29, 2511–2518 (1981).
Norman, T. R., Chamberlain, K. G. & French, M. A. Psychiatry Res. 20, 199–205 (1987).
Carr, L. A. & Rowell, P. P. Neuropharmacology 29, 311–314 (1990).
Pavlin, R. & Sket, D. Farmacentski Vest. 44, 185–192 (1993).
Yu, P. H. & Boulton, A. A. Life Sci. 41, 675–682 (1987).
Carr, L. A. & Basham, J. K. Life Sci. 48, 1173–1177 (1991).
Fowler, J. S. et al. Synapse 18, 86–93 (1994).
Boulton, A. A., Yu, P. H. & Tipton, K. F. Lancet i 114–115 (1988).
Yong, V. W. & Perry, T. L. J. neurol. Sci. 72, 265–272 (1986).
Tetrud, J. W. & Langston, J. W. Science 245, 519–522 (1989).
Tariot, P. N., Cohen, R. M., Sunderland, T., Weingartner, H. & Murphey, D, L. Psychopharmacology 91, 489–495 (1987).
Knoll, J., Yen, T. T. & Miklya, I. Life Sci. 54, 1047–1057 (1994).
Dluzen. D. E. & McDermott, J. L. J. neural Trans. 85, 145–156 (1991).
Jackson, D. M. & Westlind-Danielsson, A. in Pharmacology and Therapeutics Vol. 64 (ed. Mitchelson, F.) 291–369 (Pergamon, UK, 1994).
Di Chiara, G. & Imperato, A. Proc. natn. Acad. Sci. U.S.A. 85, 5274–5278 (1988).
Paterson, I. A., Juorio, A. V., Berry, M. D. & Zhu, M. Y. J. Pharmacol. exp. Ther. 258, 1019–1026 (1991).
Jossan, S. S., Sakurai, E. & Oreland, L. Biogenic Amines 4, 371–379 (1987).
Dougherty. E. An Introduction to Morphological Image Processing (SPIE Optical Engineering Press, Bellingham, WA, 1992).
Berlin, I. et al. Clin. Pharmac. Ther. 58, 444–452 (1995).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fowler, J., Volkow, N., Wang, GJ. et al. Inhibition of monoamine oxidase B in the brains of smokers. Nature 379, 733–736 (1996). https://doi.org/10.1038/379733a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/379733a0
This article is cited by
-
Risk factors associated with age at onset of Parkinson’s disease in the UK Biobank
npj Parkinson's Disease (2024)
-
Spread of gambling abstinence through peers and comments in online self-help chat forums to quit gambling
Scientific Reports (2022)
-
Long-term test-retest of cerebral [18F]MK-6240 binding and longitudinal evaluation of extracerebral tracer uptake in healthy controls and amnestic MCI patients
European Journal of Nuclear Medicine and Molecular Imaging (2022)
-
Association between platelet MAO activity and lifetime drug use in a longitudinal birth cohort study
Psychopharmacology (2022)
-
Does glitazone treatment have a role on the prevention of Parkinson’s disease in adult diabetic population? A systematic review
Metabolic Brain Disease (2020)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.